Next Science Limited (ASX:NXS)

Market Cap	42.43M
Revenue (ttm)	33.66M -5.3%
Net Income	-14.39M
EPS	-0.05
Shares Out	292.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,327,073
Average Volume	1,022,692
Open	0.1400
Previous Close	0.1450
Day's Range	0.1400 - 0.1450
52-Week Range	0.0560 - 0.1550
Beta	1.24
RSI	53.56
Earnings Date	Feb 26, 2026

About Next Science

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NXS

Financial Performance

In 2024, Next Science's revenue was $22.82 million, an increase of 2.87% compared to the previous year's $22.18 million. Losses were -$10.59 million, -34.94% less than in 2023.

Financial numbers in USD